Home › Companies › Axsome Therapeutics, Inc. › 2025-2026
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Axsome Therapeutics, Inc.’s Form 8-K, filed June 9, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 5, 2026: 4 items on Axsome Therapeutics, Inc.’s Form 8-K, filed June 9, 2026: 2 elected · 2 approved.
Significant dissent: 2 directors (26.4%, 23.3% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore Axsome Therapeutics, Inc. in the interactive database Compare manager voting policies
These tallies are Axsome Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 9, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Mark Saad | 28,675,654 | -- | -- | 10,286,822 | 4,815,060 | 74% | Elected | — |
| Elect Director: Susan Mahony, Ph.D., MBA | 29,892,131 | -- | -- | 9,070,345 | 4,815,060 | 77% | Elected | — |
| 2. Ratification of Appointment of Deloitte & Touche LLP | 43,278,147 | 14,407 | 484,982 | -- | 0 | 99.9% | Approved | — |
| 3. Approval, by Non-Binding Advisory Vote, of the Compensation of the Company's Named Executive Officers | 37,818,384 | 777,937 | 366,155 | -- | 4,815,060 | 98% | Approved | — |
Source: Axsome Therapeutics, Inc., Form 8-K, filed with the SEC on June 9, 2026 — read the filing on EDGAR.
See voting trends for Health Care companies, 2025-2026: shareholder support by sector and by company size.
412 asset managers disclosed a vote on at least one Axsome Therapeutics, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 7 wordings of this item as funds reported it.
74% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Mark Saad
Axsome Therapeutics, Inc.’s own tally for this item (“Elect Director: Mark Saad”): 28,675,654 for, 10,286,822 withheld, per its Form 8-K filed June 9, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The Company's stockholders elected the following directors to serve as Class II directors until the 2029 annual meeting of stockholders and until their successors are duly elected and qualified.”
Support: 74% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 105 asset managers below reported 12,163,702 for, 3,743,159 withheld, 396,743 abstained, 50 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,261,231 | 0 | 33 | 18,661 | For |
| Fidelity | 2,528,128 | 0 | 0 | 13,900 | For |
| BlackRock | 2,051,700 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 0 | 0 | 931,652 | Withhold |
| Invesco | 853,953 | 0 | 0 | 0 | For |
| First Trust | 0 | 0 | 0 | 561,179 | Withhold |
| MUTUAL FUND SERIES TRUST | 496,558 | 0 | 0 | 6,438 | For |
| Delaware/Macquarie | 0 | 0 | 0 | 444,493 | Withhold |
| Charles Schwab | 393,406 | 0 | 0 | 110 | For |
| TIAA | 0 | 0 | 0 | 252,697 | Withhold |
| Jackson National | 212,271 | 0 | 32,776 | 0 | Mixed |
| Putnam | 190,657 | 0 | 0 | 0 | For |
| Principal | 0 | 0 | 0 | 169,495 | Withhold |
| Manager Directed Portfolios | 168,240 | 0 | 0 | 0 | For |
| Brighthouse | 81,393 | 0 | 0 | 79,391 | Mixed |
| Columbia Threadneedle | 0 | 0 | 0 | 153,831 | Withhold |
| John Hancock | 11,796 | 0 | 137,462 | 0 | Mixed |
| Loomis Sayles | 0 | 0 | 139,821 | 0 | Abstain |
| Franklin Custodian Funds | 0 | 0 | 0 | 128,461 | Withhold |
| Voya | 0 | 0 | 0 | 116,066 | Withhold |
| Waddell & Reed | 0 | 0 | 0 | 103,315 | Withhold |
| Royce | 93,662 | 0 | 0 | 0 | For |
| Equitable | 58,901 | 0 | 0 | 34,249 | Mixed |
| Hartford | 91,430 | 0 | 0 | 0 | For |
| Nuveen | 0 | 0 | 0 | 76,149 | Withhold |
Showing the 25 largest of 105 asset managers. All 105 are in the interactive database (link above).
Combines 8 wordings of this item as funds reported it.
77% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Susan Mahony, Ph.D., MBA
Axsome Therapeutics, Inc.’s own tally for this item (“Elect Director: Susan Mahony, Ph.D., MBA”): 29,892,131 for, 9,070,345 withheld, per its Form 8-K filed June 9, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The Company's stockholders elected the following directors to serve as Class II directors until the 2029 annual meeting of stockholders and until their successors are duly elected and qualified.”
Support: 77% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 105 asset managers below reported 12,437,850 for, 3,469,184 withheld, 396,570 abstained, 50 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,263,496 | 0 | 29 | 16,400 | For |
| Fidelity | 2,528,128 | 0 | 0 | 13,900 | For |
| BlackRock | 2,051,700 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 0 | 0 | 931,652 | Withhold |
| Invesco | 853,953 | 0 | 0 | 0 | For |
| First Trust | 0 | 0 | 0 | 561,179 | Withhold |
| MUTUAL FUND SERIES TRUST | 496,558 | 0 | 0 | 6,438 | For |
| Delaware/Macquarie | 0 | 0 | 0 | 444,493 | Withhold |
| Charles Schwab | 393,516 | 0 | 0 | 0 | For |
| TIAA | 0 | 0 | 0 | 252,697 | Withhold |
| Jackson National | 212,271 | 0 | 32,776 | 0 | Mixed |
| Putnam | 190,657 | 0 | 0 | 0 | For |
| Principal | 0 | 0 | 0 | 169,495 | Withhold |
| Manager Directed Portfolios | 168,240 | 0 | 0 | 0 | For |
| Brighthouse | 81,393 | 0 | 0 | 79,391 | Mixed |
| Columbia Threadneedle | 153,831 | 0 | 0 | 0 | For |
| John Hancock | 11,796 | 0 | 137,462 | 0 | Mixed |
| Loomis Sayles | 0 | 0 | 139,821 | 0 | Abstain |
| Franklin Custodian Funds | 0 | 0 | 0 | 128,461 | Withhold |
| Voya | 0 | 0 | 0 | 116,066 | Withhold |
| Waddell & Reed | 0 | 0 | 0 | 103,315 | Withhold |
| Royce | 93,662 | 0 | 0 | 0 | For |
| Equitable | 58,901 | 0 | 0 | 34,249 | Mixed |
| Hartford | 91,430 | 0 | 0 | 0 | For |
| Nuveen | 0 | 0 | 0 | 76,149 | Withhold |
Showing the 25 largest of 105 asset managers. All 105 are in the interactive database (link above).
Combines 7 wordings of this item as funds reported it.
98% Approved · of votes cast
Prior year: 98.5% for (June 6, 2025 meeting) ▼ 0.5 pts
Description as filed by funds: To approve, by non-binding advisory vote, the compensation of our named executive officers.
Axsome Therapeutics, Inc.’s own tally for this item (“3. Approval, by Non-Binding Advisory Vote, of the Compensation of the Company's Named Executive Officers”): 37,818,384 for, 777,937 against — passed, per its Form 8-K filed June 9, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders voted to approve, by non-binding advisory vote, the compensation of the Company's named executive officers.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,279,922 | 3 | 1 | 0 | For |
| Fidelity | 2,542,028 | 0 | 0 | 0 | For |
| BlackRock | 2,051,700 | 0 | 0 | 0 | For |
| T. Rowe Price | 931,652 | 0 | 0 | 0 | For |
| Invesco | 853,953 | 0 | 0 | 0 | For |
| First Trust | 561,179 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 502,996 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 444,493 | 0 | 0 | 0 | For |
| Charles Schwab | 393,516 | 0 | 0 | 0 | For |
| TIAA | 252,697 | 0 | 0 | 0 | For |
| Jackson National | 245,047 | 0 | 0 | 0 | For |
| Putnam | 190,657 | 0 | 0 | 0 | For |
| Principal | 169,495 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 168,240 | 0 | 0 | 0 | For |
| Brighthouse | 160,784 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 153,831 | 0 | 0 | 0 | For |
| John Hancock | 149,258 | 0 | 0 | 0 | For |
| Loomis Sayles | 139,821 | 0 | 0 | 0 | For |
| Franklin Custodian Funds | 128,461 | 0 | 0 | 0 | For |
| Voya | 116,066 | 0 | 0 | 0 | For |
| Waddell & Reed | 103,315 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 97,977 | 0 | 0 | 0 | For |
| Royce | 93,662 | 0 | 0 | 0 | For |
| Equitable | 93,150 | 0 | 0 | 0 | For |
| Hartford | 91,430 | 0 | 0 | 0 | For |
Fund voting reports, all 104 managers: 16,345,560 for, 5,246 against, 3,589 abstained, 50 not voted, 94 mixed. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 1,646,603 | 0 | 0 | 0 | For |
| BlackRock | 1,606,751 | 8,809 | 0 | 0 | For |
| Invesco | 1,528,689 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,409,788 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,163,544 | 0 | 0 | 0 | For |
| State Street | 888,250 | 1,327 | 0 | 0 | For |
| Wellington | 839,000 | 0 | 0 | 0 | For |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 737,578 | 0 | 0 | 0 | For |
| NOMURA INVESTMENT MANAGEMENT BUSINESS TRUST | 702,773 | 0 | 0 | 0 | For |
| Charles Schwab | 395,169 | 0 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 369,389 | 0 | 0 | 0 | For |
| Northern Trust | 360,749 | 2,848 | 0 | 0 | For |
| Vanguard | 358,026 | 0 | 0 | 0 | For |
| Nuveen | 335,760 | 0 | 0 | 0 | For |
| Hood River Capital Management LLC | 311,038 | 0 | 0 | 0 | For |
| Putnam | 285,361 | 0 | 0 | 0 | For |
| Citadel | 266,615 | 0 | 0 | 0 | For |
| Loomis Sayles | 247,919 | 0 | 0 | 0 | For |
| PRINCIPAL GLOBAL INVESTORS | 233,446 | 0 | 0 | 0 | For |
| ORBIMED ADVISORS LLC | 213,921 | 0 | 0 | 0 | For |
| PNC BANK, NATIONAL ASSOCIATION | 201,048 | 0 | 0 | 0 | For |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | 200,357 | 0 | 0 | 0 | For |
| Point72 | 199,671 | 0 | 0 | 0 | For |
| DE Shaw | 186,859 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 171,139 | 0 | 0 | 0 | For |
Institutional-manager reports, all 337 managers: 19,198,702 for, 358,174 against, 5,429 abstained, 873 not voted. Showing the 25 largest; every one is in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
99.9% Approved · of votes cast
Description as filed by funds: TO RATIFY THE APPOINTMENT OF DELOITTE & TOUCHE LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2026.
Axsome Therapeutics, Inc.’s own tally for this item (“2. Ratification of Appointment of Deloitte & Touche LLP”): 43,278,147 for, 14,407 against — passed, per its Form 8-K filed June 9, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 104 asset managers below reported 16,295,166 for, 3,588 abstained, 50 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,279,925 | 0 | 0 | 0 | For |
| Fidelity | 2,542,028 | 0 | 0 | 0 | For |
| BlackRock | 2,051,700 | 0 | 0 | 0 | For |
| T. Rowe Price | 931,652 | 0 | 0 | 0 | For |
| Invesco | 853,953 | 0 | 0 | 0 | For |
| First Trust | 561,179 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 502,996 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 444,493 | 0 | 0 | 0 | For |
| Charles Schwab | 393,516 | 0 | 0 | 0 | For |
| TIAA | 252,697 | 0 | 0 | 0 | For |
| Jackson National | 245,047 | 0 | 0 | 0 | For |
| Putnam | 190,657 | 0 | 0 | 0 | For |
| Principal | 169,495 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 168,240 | 0 | 0 | 0 | For |
| Brighthouse | 160,784 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 153,831 | 0 | 0 | 0 | For |
| John Hancock | 149,258 | 0 | 0 | 0 | For |
| Loomis Sayles | 139,821 | 0 | 0 | 0 | For |
| Franklin Custodian Funds | 128,461 | 0 | 0 | 0 | For |
| Voya | 116,066 | 0 | 0 | 0 | For |
| Waddell & Reed | 103,315 | 0 | 0 | 0 | For |
| Royce | 93,662 | 0 | 0 | 0 | For |
| Equitable | 93,150 | 0 | 0 | 0 | For |
| Hartford | 91,430 | 0 | 0 | 0 | For |
| Nuveen | 76,149 | 0 | 0 | 0 | For |
Showing the 25 largest of 104 asset managers. All 104 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 51,459,766 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 8.32% |
| 2 | Fidelity | 4.94% |
| 3 | BlackRock | 3.99% |
| 4 | T. Rowe Price | 1.81% |
| 5 | Invesco | 1.66% |
| 6 | First Trust | 1.09% |
| 7 | MUTUAL FUND SERIES TRUST | 0.98% |
| 8 | Delaware/Macquarie | 0.86% |
| 9 | Charles Schwab | 0.76% |
| 10 | TIAA | 0.49% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 3.20% |
| 2 | BlackRock | 3.14% |
| 3 | Invesco | 2.97% |
| 4 | T. Rowe Price | 2.74% |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 2.26% |
| 6 | State Street | 1.73% |
| 7 | Wellington | 1.63% |
| 8 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.43% |
| 9 | NOMURA INVESTMENT MANAGEMENT BUSINESS TRUST | 1.37% |
| 10 | Charles Schwab | 0.77% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| Herriot Tabuteau, M.D. | 8,992,422 | 17.47% | Proxy statement (DEF 14A), proxy filed April 24, 2026 |
| Antecip Capital LLC | 7,344,500 | 14.27% | Proxy statement (DEF 14A), proxy filed April 24, 2026 |
| Vanguard Group | 4,164,818 | 8.09% | Form 13F, quarter ended March 31, 2026 |
| BlackRock | 3,912,844 | 7.60% | Form 13F, quarter ended March 31, 2026 |
| FMR (Fidelity) | 1,566,995 | 3.05% | Form 13F, quarter ended March 31, 2026 |
| T. Rowe Price | 1,317,059 | 2.56% | Form 13F, quarter ended March 31, 2026 |
| Invesco | 1,297,678 | 2.52% | Form 13F, quarter ended March 31, 2026 |
| Geode Capital | 1,162,981 | 2.26% | Form 13F, quarter ended March 31, 2026 |
| Wellington Management | 1,145,306 | 2.23% | Form 13F, quarter ended March 31, 2026 |
| State Street | 986,809 | 1.92% | Form 13F, quarter ended March 31, 2026 |
Percentages above are of 51,459,766 shares outstanding, as reported by Axsome Therapeutics, Inc. on its Form 10-Q dated April 27, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At Axsome Therapeutics, Inc.'s shareholder meeting held June 5, 2026, in the 2025-2026 proxy season, 412 asset managers reported votes on at least one of its 4 ballot items in their SEC Form N-PX filings, covering 1,898 separate fund positions. On the most widely held item on that ballot — To approve, by non-binding advisory vote, the compensation of our named executive officers. — Axsome Therapeutics, Inc.'s filing reports the proposal as approved, with 98% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Axsome Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 9, 2026.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Axsome Therapeutics, Inc.’s 10-Q dated April 27, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
Axsome Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Proxy Votes Now, “Axsome Therapeutics (AXSM) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/axsome-therapeutics-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.